English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The field of primary headaches and cranial neuralgias has experienced in a relatively brief period a startling progress in expansion of knowledge (1, 2). This has allowed partial unraveling of the machinery involved in the occurrence of attacks and the identification of a set of mediators and genes that are likely to play a role. In the case of migraine, accumulated evidence has very recently led to the development of the first disease-specific prophylactic drug, the CGRP antibodies (3). In other cases, drugs available for indications different from pain, such as botulinum toxin or the antiepileptic drugs, have been tested with adapted protocols proving effective in chronic migraine and showing potential efficacy in other cranial pains, i.e., cluster headache, trigeminal neuralgia, and temporomandibular joint disorder (4, 5). Notwithstanding the undeniable scientific advances, much research is still needed to fully understand and effectively treat primary headaches and cranial neuralgias. Open issues are manifold, spanning from pathophysiology to clinical aspects, and represent exciting challenges for future research.

frontiers in neurology

The Grand Challenge in Cranial Pain—From Migraine to Cranial Neuralgias: Understanding Differences and Similarities to Advance Knowledge and Management